NEWS 2007
[07/18/2007]
Mitsui Ventures Launching a New Approach to Seed Financing
Leveraging Japanese LLC Structure to Develop Preclinical Compounds
Mitsui Ventures has introduced a unique method, utilizing Japanese LLC structure, to offer seed financing to drug development programs in preclinical stage.
Under this approach, the respective contributions of inventor and sponsor are valued and represented in a fair manner, and the funds will be disbursed as the milestones are reached. Upon successful collection of targeted data, LLC will be converted to a Japanese corporation with a management team set in place for further development.
As its first example, Tsuyashin LLC has been established to develop a novel anticancer drug that has proven its efficacy in animal models.
Mitsui Ventures plans to further this approach, aiming to facilitate development of drug candidates that have animal POC data available, but may be at a too early stage, in the traditional view of Japanese market, to form a corporation. We continue to provide financing for data collection and analysis regarding drug development programs that have distinctive and attractive features and a potential for a strong IP position in major markets.
